Precigen recently shared positive news on the clinical progress of five pipeline candidates. Three were developed using Precigen’s Ultra-CAR-T platform: PRGN-3005 being developed for advanced, recurrent platinum resistant ovarian cancer; PRGN-3006 for relapsed or refractory acute myeloid leukemia; and PRGN-3007, for which the FDA has cleared IND application to launch a Phase I/Ib open-label trial in advanced ROR1+ hematological and solid tumors . . .
![Spark Therapeutics saw its share price tumble about 30% in early-morning trading after it reported mixed preliminary data this morning from a Phase I/II trial of its hemophilia A gene therapy candidate SPK-8001. [Source: wildpixel/Getty Images]](https://www.genengnews.com/wp-content/uploads/2018/08/Dec7_2017_Getty_487489316_GeneTherapy_60019871441892139879144-100x70.jpg "Spark Therapeutics Stock Tumbles after Mixed Results from Phase I/II Trial of Hemophilia A Candidate")